nach oben

HNO

Erschienen in:

01.07.2012 | Originalien

Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis

Teil 1: Pathophysiologie, molekulare Grundlagen

verfasst von: Prof. Dr. L. Klimek, P. Högger, O. Pfaar

Erschienen in: HNO | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die allergische Rhinitis ist eine häufige Atemwegserkrankung, die durch eine Hyperreaktivität der Schleimhaut, erhöhte Sekretion und Entzündungsprozesse sowie einen hiermit einhergehenden Gewebsumbau („remodelling“) charakterisiert ist. Die Gabe antiallergischer und antiinflammatorischer Medikamente wie nasaler Glukokortikosteroide (nGCS) stellt hierbei die wichtigste Therapiemaßnahme dar.

nGCS üben über mindestens zwei verschiedene Mechanismen einen antiinflammatorischen Effekt aus: zum einen durch Transaktivierung, zum anderen durch Transrepression. Darüber hinaus wird GCS eine regulatorische Funktion zugeschrieben, indem sie regulatorische Zytokine und Forkhead Box P3 (Foxp3) induzieren. Foxp3 ist ein wichtiger Transkriptionsfaktor regulatorischer T-Zellen, der es ermöglicht, andere CD4 ⁺- Zellen in ihrer Effektorfunktion und Proliferation zu inhibieren.

Das Wissen über die Kenntnisse der molekularen Mechanismen erlaubt heute, die antiinflammatorischen Wirkung von nGCS gezielter und frühzeitiger zu nutzen.

Brozek JL, Bousquet J, Baena-Cagnani CE et al (2010) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126(3):466–476PubMedCrossRef

Ring J, Bachert C, Bauer CP, Czech W (2010) Weißbuch: Allergie in Deutschland. Urban & Vogel, München

Bousquet J, Jacquot W, Vignola M et al (2004) Allergic rhinitis: a disease remodeling the upper airways? J Allergy Clin Immunol 113:43–49PubMedCrossRef

Kimmerle R, Rolla AR (1985) Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med 79:535–537PubMedCrossRef

Masuyama K (2000) Merits and demerits of steroid – different whole body and limited part administering. J Jpn Immunol Allergol Otolaryngol 18:6–11

Derendorf H, Meltzer EO (2008) Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 63:1292–1300PubMedCrossRef

Wan H, Winton HL, Soeller C et al (1999) Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 104:123–133PubMedCrossRef

Hottori H, Okano M, Yoshino T et al (2001) Expression of costimulatory CD80/CD86-CD28/CD152 molecules in nasal mucosa of patients with perennial rhinitis. Clin Exp Allergy 31:1242–1249CrossRef

Klimek L, Pfaar O (2011) Allergische Rhinitis: Immunologische und neurogene Mechanismen. HNO 59:1191–1197PubMedCrossRef

10.

Kleinjan A, Willart M, Rijt LS van et al (2006) An essential role for dendritic cells in human and experimental allergic rhinitis. J Allergy Clin Immunol 118:1117–1125PubMedCrossRef

11.

Akdis M, Verhagen A, Taylor F et al (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199:1567–1575PubMedCrossRef

12.

Sokol CL, Barton GM, Farr AG, Medzhitov R (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 9:310–318PubMedCrossRef

13.

Okano M, Yoshino T, Nishizaki K et al (2000) Interleukin-4 independent production of T_H2 cytokines by nasal lymphocytes and nasal eosinophilia in murine allergic rhinitis. Allergy 55:723–731PubMedCrossRef

14.

Hattori H, Okano M, Kariya S et al (2006) Signals through CD40 play a critical role in the pathophysiology of Schistosoma mansoni egg antigen-induced allergic rhinitis in mice. Am J Rhinol 20:165–169PubMed

15.

Flynn AN, Itani OM, Moninger TO, Welsh MJ (2009) Acute regulation of tight junction ion selectivity in human airway epithelia. Proc Natl Acad Sci U S A 106:3591–3596PubMedCrossRef

16.

Takano K, Kojima T, Go M et al (2005) and CD11c-positive dendritic cells penetrate beyond well-developed epithelial tight junctions in human nasal mucosa of allergic rhinitis. J Histochem Cytochem 53:611–619PubMedCrossRef

17.

Gelfand EW (2004) Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 114:135–138CrossRef

18.

Nomiya R, Okano M, Fujiwara T et al (2008) CR T_H2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. J Immunol 180:5680–5688PubMed

19.

Choi GS, Pard HJ, Hur GY et al (2009) Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 39:655–661PubMedCrossRef

20.

Durham SR, Ying S, Varney VA et al (1992) Cytokine messenger RNA expression for IL-4, IL-4, IL-5, and granulocyte/macrophage colony stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 148:2390–2394PubMed

21.

Hogan SP, Rosenberg HF, Moqbel R et al (2008) Eosinophil: biological properties and role in health and disease. Clin Exp Allergy 38:709–750PubMedCrossRef

22.

Takahashi N, Yamada T, Narita N, Fujieda S (2006) Double-stranded RNA induces production of RANTES and IL-8 by human nasal fibroblasts. Clin Immunol 118:51–58PubMedCrossRef

23.

Marcucci F, Sensi LG, Migali E, Coniglio G (2001) Eosinophilic cationic protein and specific IgE in serum and nasal mucosa of patients with grass-pollen-allergic rhinitis and asthma. Allergy 56:231–236PubMedCrossRef

24.

Iwasaki M, Saito K, Tekemura M et al (2003) TNF-alpha contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 112:134–140PubMedCrossRef

25.

Bousquet J, Vignola AM, Campbell AM, Michel FB (1996) Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 110:207–218PubMedCrossRef

26.

Fujita M, Yonetomi Y, Shimouchi K et al (1999) Involvement of cysteinyl leukotriens in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol 369:349–356PubMedCrossRef

27.

Heppt W, Dinh QT, Cryer A et al (2004) Phenotypic alteration of neuropeptide-containing nerve fibers in seasonal intermittent allergic rhinitis. Clin Exp Allergy 34:1105–1110PubMedCrossRef

28.

Imanura T, Kambara T (1992) Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs. Agents Actions 37:245–249CrossRef

29.

Nabe T, Tsuzuike N, Ohtani Y et al (2008) Important roles of tachykinines in the development of allergic nasal hyperresponsiveness in guinea-pigs. Clin Exp Allergy 39:138–146PubMedCrossRef

30.

Baroody FM, Ford S, Lichtenstein LM et al (1994) Physiologic responses and histamine release after nasal antigen challenge. Effect of atropine. Am J Respir Crit Care Med 149:1457–1465PubMed

31.

Sheaham P, Walsh RM, Walsh MA, Costello RW (2005) Induction of nasal hyper-responsiveness by allergen challenge in allergic rhinitis: the role of afferent and efferent nerves. Clin Exp Allergy 35:45–51CrossRef

32.

Bresciani M, Laliberte F, Laliberte MF et al (2009) Nerve growth factor localization in the nasal mucosa of patients with persistent allergic rhinitis. Allergy 64:112–117PubMedCrossRef

33.

Konno A, Terada N, Okamoto Y, Togawa K (1987) The role of chemical mediators and mucosal hyperreactivity in nasal in nasal hypersecretion in nasal allergy. J Allergy Clin Immunol 79:620–627PubMedCrossRef

34.

Struben VM, Wieringa MH, Feenstra L, Jongste JC de (2006) Nasal nitric oxide and nasal allergy. Allergy 61:665–670PubMedCrossRef

35.

Sikoff PE, Roth Y, McClean P et al (1999) Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Ann Otol Rhinol Laryngol 108:368–372

36.

Tanaka Y, Mizutani N, Fujii M et al (2006) Different mechanisms between thromboxane A2- and leukotriene D4-induced nasal blockage in guinea-pigs. Prostaglandins Other Lipid Mediat 80:144–154PubMedCrossRef

37.

Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedCrossRef

38.

Pratt WB, Morishima Y, Murphy M, Harrel M (2006) Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 172:111–138PubMedCrossRef

39.

Grad I, Picard D (2007) The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 274:2–12CrossRef

40.

Oakley RH, Jewell CM, Yudt MR et al (1999) The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 274:27857–27866PubMedCrossRef

41.

Fakhri S, Tulic M, Christodoulopoulos P et al (2004) Microbial superantigens induce glucocorticoid receptor β and steroid resistance in a nasal explants model. Laryngoscope 114:887–892PubMedCrossRef

42.

Barnes PJ (2006) Corticosteroid effects on cell signaling. Eur Respir J 27:413–426PubMedCrossRef

43.

Graversen JH, Madsen M, Moestrup SK (2002) CD163: a signal receptor scavenging haptoglobin–hemoglobin complex from plasma. Int J Biochem Cell Biol 34:309–314PubMedCrossRef

44.

Pascual G, Glass CK (2006) Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17:321–327PubMedCrossRef

45.

Saito M, Takayanagi R, Goto K et al (2002) The presence of both the amino- and carboxyl-terminal domains in the AR is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: a three-dimensional imaging study. Mol Endocrinol 16:694–706CrossRef

46.

Smith SJ, Piliponsky AM, Rosenhead F et al (2002) Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy 32:906–913PubMedCrossRef

47.

Crocker IC, Zhou CY, Bewta AK et al (1997) Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 78:497–505PubMedCrossRef

48.

Stellato C, Atsuta J, Bickel CA, Schleimer RP (1999) An in vitro comparison of commonly used topical glucocotricoid preparations. J Allergy Clin Immunol 104:623–629PubMedCrossRef

49.

Ciprandi G, Tosca MA, Passalacqua G, Canonica GW (2001) Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann Allergy Asthma Immunol 86:433–438PubMedCrossRef

50.

Meagher LC, Cousin JM, Seckl JR, Haslett C (1996) Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156:4422–4428PubMed

51.

Till SJ, Jacobson MR, O’Brien F et al (2001) Recruitment of CD1a ⁺ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy. Allergy 56:126–131PubMedCrossRef

52.

Erin EM, Zacharasiewicz AS, Nicholson GC et al (2005) Topical corticosteroid inhibits interleukin-4, -5, and −13 in nasal secretions following allergen challenge. Clin Exp Allergy 35:1608–1614PubMedCrossRef

53.

Malmhall C, Bossios A, Pullertis T, Lotvall J (2007) Effects of pollen and nasal glucocorticoids on FOXP3 ⁺, GATA-3 ⁺ and T-bet ⁺ cells in allergic rhinitis. Allergy 62:1007–1013PubMedCrossRef

54.

Durham SR, Gould HJ, Thiense CP et al (1997) Expression of epsilon germ-line transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 27:2599–2906CrossRef

55.

Mullol J, Roca-Ferrer J, Xaubet A et al (2000) Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. Respir Med 94:428–431PubMedCrossRef

56.

Silvestri M, Sabatini F, Scarso L et al (2002) Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling. Int Arch Allergy Immunol 128:51–58PubMedCrossRef

57.

Namba M, Asano K, Kanai K et al (2004) Suppression of matrix metalloproteinase production from nasal fibroblasts by fluticasone propionate in vitro. Acta Otolaryngol 124:964–969PubMedCrossRef

58.

Uchida J, Kanai K, Asano K et al (2004) Influence of fluticasone propionate on the production of vascular endothelial growth factor and basic fibroblast growth factor from nasal fibroblasts in vitro. In Vivo 18:767–770PubMed

59.

Yamamoto Y, Ikeda K, Watanabe M et al (1998) Expression of adhesion molecules in cultured human nasal mucosal microvascular endothelial cells activated by interleukin-1 beta or tumor necrosis factor-alpha: effects of dexametasone. Int Arch Allergy Immunol 117:68–77PubMedCrossRef

60.

Hamilos DL, Thawley SE, Kramper MA et al (1999) Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflamatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 103:79–87PubMedCrossRef

61.

Tingsgaard PK, Bock T, Larsen PL, Tos M (1999) Topical budesonide treatment reduces endothelial expression of intracellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps. Acta Otolaryngol 119:362–368PubMedCrossRef

62.

Greiff L, Andersson M, Svensson C et al (1994) Glucocorticoids may not inhibit plasma exudation by direct vascular antipermeability effects in human airways. Eur Respir J 7:1120–1124PubMed

63.

Shevach EM, DiPaolo RA, Andersson J et al (2006) The lifestyle of naturally occurring CD4 ⁺ CD25 ⁺ Foxp3 ⁺ regulatory T cells. Immunol Rev 212:60–73PubMedCrossRef

64.

Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775–787PubMedCrossRef

65.

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061PubMedCrossRef

66.

Ryanna K, Stratigou V, Safinia N, Hawrylowicz C (2009) Regulatory T cells in bronchial asthma. Allergy 64:335–347PubMedCrossRef

67.

Grindebacke H, Wing K, Andersson AC et al (2004) Defective suppression of T_H2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 34:1364–1372PubMedCrossRef

68.

Jutel M, Akdis M, Budak F et al (2003) IL-10 and TGF-beta cooperate in the regulatory T cell responses to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33:1205–1214PubMedCrossRef

69.

Klimek L, Schendzielorz P, Högger P (2010) Nasale Glukokortikosteroid-Therapie: Ein Update. Allergologie 34(6):307–318

Titel: Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis
Teil 1: Pathophysiologie, molekulare Grundlagen
verfasst von: Prof. Dr. L. Klimek
P. Högger
O. Pfaar
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: HNO / Ausgabe 7/2012
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-012-2483-4

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis

Teil 1: Pathophysiologie, molekulare Grundlagen

Zusammenfassung

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Perforation der A. carotis communis als Ursache eines Halsgefäßscheidenhämatoms

Subglottische Stenosen im 1. Lebensjahr

„Flaring spreader flaps“ und „upper lateral advancement“

Laryngomalazie

Pädiatrische Laryngologie

Abstracts des 2. Workshops zur experimentellen und klinischen Kopf-Hals-Onkologie in Lübeck 09.-10.02.2012

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO